Look Your Best, Feel Your Best, and Be Your Best With AAIClinics
Call Us
(866) 224-5698
Mon-Fri: 10am-6pm
Sat-Sun: Closed
May 7, 2019 by admin 0 Comments

Post Cycle Therapy & well-Structured Testosterone Therapy

The Post Cycle Therapy (PCT), and Testosterone Injections Therapy goes hand on hand, Most men embarking on a testosterone injectable therapy replacement protocol are doing so as a result of medical reason or age-related issues that are affecting their life.

Now patients with problems and that face their low testosterone, the related concerns and do not allow fully experience the decline associated with maintaining extended periods of low hormones levels and will usually benefit from comprehensive testosterone therapy.

Note: that the specific drug and dose prescribed will depend on the particular information contained within each patient medical file and medical reason, as well as the individual goals patients.

Example:

  • Day 1. (50–250 mg) of testosterone injection.
  • Day 2. Two estrogen blocker or inhibitor.
  • Day 3. One injectable of an amino acid or vitamin B-vitamin.
  • Day 5. One estrogen blocker or inhibitor by mouth.
  • Day 6. One injection of a (250–800 units) of testosterone secretagogue.
  • Day 7. One estrogen blocker or inhibitor (sometimes two estrogen blockers a week is enough, But depending on the patient file).
  • Day 7. One injection of a (250–800 units) of testosterone secretagogue.

Example: This protocol for a man focused on muscle development (reversing lean muscle loss), Muscle development protocols, also work well in patients that may react to therapy with too much aromatization (estrogen accumulation).

Men are experiencing excessive aromatization and lean muscle depletion who are focused on rebuilding muscle, with Peptides.

Note: that the specific drug and dose prescribed will depend on the particular information contained within each patient medical file, as well as the individual patient goals.

Example:

  • Day 1. (50–150 mg) of a combination of testosterone esters,
    (15–30 units) Sermorelin Peptides before Bedtime.
  • Day 2. Two estrogen blocker or inhibitor,
    (15–30 units) Sermorelin Peptides before Bedtime.
  • Day 3. One injection of an amino acid or B-vitamin,
    (15–30 units) Sermorelin Peptides before Bedtime.
  • Day 4. Combination of (50–150 mg) testosterone esters,
    (15–30 units) Sermorelin Peptides before Bedtime.
  • Day 5. One estrogen blocker or inhibitor by mouth,
    (15–30 units) Sermorelin Peptides before Bedtime.
  • Day 6. One injection of a (250–800 units) of testosterone secretagogue.
  • Day 7. One estrogen blocker or inhibitor (sometimes two estrogen blockers a week is enough, But depending on the patient file).
  • Day 7. One injection of a (250–800 units) of testosterone secretagogue.

This weekly cycle would typically continue for 6–9 months, before a break period in which the body is allowed to normalize and reactivate your natural production.

What is Sermorelin?

Sermorelin is a peptide comprised of the first 29 amino acids of endogenous GH; the sequence is the same as endogenous GHRH. As we age, our body produces less and less of our vital hormones, including GH. Studies have revealed that sermorelin can restore GH RNA concentrations to youthful levels, which subsequently stimulates the production of insulin-like growth factor-1 (IGF-1).

Remember: When you are artificially manipulating your testosterone levels, some other functions of the body stop operating since endogenous testosterone production is shut down because of the presence of high levels of exogenous hormone. You will need Post Cycle Therapy on your break from testosterone therapy.

Break Period: Generally referred to as the Post Cycle Therapy (PCT), consists of medications that are formulated to reactivate the dormant systems that we have not used while your testosterone Injections therapy.

The essential functions that need to reactivate with your
Post Cycle Therapy:

  • FSH (follicle-stimulating hormone): This will stimulate sperm production in the testes.
  • LH (luteinizing hormone): This will stimulate testosterone production in the testes.

The reason why is because estrogen accumulation after extended periods of high testosterone levels, and water retention can cause, decreased libido, and other side effects associated with high estradiol levels from past testosterone therapy.

Well-structured Testosterone Injection Therapy

Following Results:

  • Week One: If you have never received testosterone injections before and are suffering from hypogonadism (clinically low testosterone), you should begin to experience invaluable changes just 3 or 4 days after your first administration. You should sleep better and have more energy.
  • Week Two: Morning erections make a significant comeback! In men with erectile dysfunction problems, morning erections help to determine if their problems stem from a psychological or a physiological problem.
  • Week Three: You will begin to notice a sense of clarity as your cognitive function improves. Your ability to recall information and your articulation will improve. You will suddenly realize that you feel more mentally sharp and able, which will allow you to better cope with stress and pressure.
  • The End of Month One: Your energy levels should be noticeably increased throughout the day.
  • Month Two: The same health manifestations that you were experiencing throughout your first month should continue to develop and improve. Your energy levels should still be increasing, and you should have a stronger “go-getter” attitude.
  • Month Three: There should now be a significant, noticeable difference in your energy level and output. Your workouts will require less effort and will yield quicker, more visible results. The time you need for muscle healing and recuperation after exercise should be reduced.
  • Month Four: By now, your endurance, stamina, exercise potential, and overall performance ability should supersede all your expectations. If you have never been on testosterone therapy before your first program and you have been eating well and exercising from the beginning, you will be surprised at the level of transformation you have experienced. Furthermore, it will be evident that these results and this amount of energy output would not be possible without restoring your testosterone levels to the numbers had in your youth.
  • Month Five: The changes and improvements in your physical performance, ability, and growth will be fantastic. If you were experiencing mental problems such as sadness, depression, anxiety, or even mental fatigue, by now you should notice substantial progress in your ability to deal with unpleasant or challenging scenarios and circumstances. Remember that all the other positive changes you have experienced will also contribute to a sense of self-improvement. This makes you naturally feel better about your progression and growth. More importantly, the physiological changes in brain chemical secretion add to your sense of fulfillment, happiness, and overall well-being.
  • Month Six: All individuals are receiving testosterone experience different effects by six months of therapy. What you experience will also depend on how many cycles of testosterone therapy you have participated in previously. Sometimes, a user’s sense of improvement begins to dwindle or remain stagnant. The body can become used to the type, or ester, of testosterone that is being used if the same therapy is continued for more than 1 or 2 years. Also, because other processes in the body cease to function when testosterone levels are manipulated using testosterone injections, the benefits of therapy begin to diminish and the “feel good” scenarios that were being experienced stopped.

Well-structured Sermorelin Therapy:

Month one:

  • Increased energy
  • Deeper, more restful sleep
  • Improved stamina
  • A more content state of mind

Month Two:

  • Reduced belly fat
  • Improved metabolism
  • The return of some muscle tone
  • Improved skin tone and fewer wrinkles
  • Stronger hair and nails

Month Three:

  • Increased mental focus
  • Improved flexibility and joint health
  • More feelings of drive and ambition
  • Enhanced sex drive and performance

Month Four:

  • Improved mental acuity
  • Better skin elasticity
  • Further improved appearance of the hair and nails
  • Continued weight loss
  • Increased lean muscle mass

Month Five:

  • Continued loss of belly fat
  • Improved skin tone with the reduced appearance of wrinkles
  • Noticeably fuller, healthier hair

Month Six:

  • A 5–10% reduction in body fat, without diet or exercise
  • A 10% increase in lean muscle mass
  • Significantly improved physique
  • Increased vitality dies to organ regrowth (vital organs, including the brain, shrink with age)

February 4, 2016 by admin 0 Comments

Testosterone Cypionate Description

Testosterone Cypionate description injections

Testosterone Cypionate Description injection for intramuscular injection contains Testosterone Cypionate which is the oil-soluble 17 (beta)- cyclopentyl propionate ester of the androgenic hormone testosterone. Testosterone Cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for Testosterone Cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1-oxopropoxy)-, (17β)-. Its molecular formula is C27H40O3, and the molecular weight 412.61.

The structural formula is represented below:

Testosterone Cypionate injection, USP is available in two strengths, 100 mg/mL and 200 mg/mL Testosterone Cypionate, USP.

Each mL of the 100 mg/mL solution contains:

Testosterone Cypionate……………………………………………………………………. 100 mg
Benzyl benzoate ……………………………………………………………………………… 0.1 mL
Cottonseed oil ………………………………………………………………………………… 736 mg
Benzyl alcohol (as preservative)………………………………………………………… 9.45 mg

Each mL of the 200 mg/mL solution contains:

Testosterone Cypionate……………………………………………………………………. 200 mg
Benzyl benzoate………………………………………………………………………………. 0.2 mL
Cottonseed oil………………………………………………………………………………… 560 mg

Benzyl alcohol (as preservative)………………………………………………………… 9.45 mg

Testosterone Cypionate – Clinical Pharmacology

Endogenous androgens are responsible for normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include growth and maturation of the prostate, seminal vesicles, penis, and scrotum; development of male hair distribution, such as beard, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Drugs in this class also cause retention of nitrogen, sodium, potassium, and phosphorous, and decreased urinary excretion of calcium. Androgens have been reported to increase protein anabolism and decrease protein catabolism. Nitrogen balance is improved only when there is sufficient intake of calories and protein.

Androgens are responsible for the growth spurt of adolescence and for eventual termination of linear growth, brought about by fusion of the epiphyseal growth centers. In children, exogenous androgens accelerate linear growth rates but may cause a disproportionate advancement in bone maturation. Use over long periods may result in fusion of the epiphyseal growth centers and termination of the growth process. Androgens have been reported to stimulate the production of red blood cells by enhancing production of erythropoietic stimulation factor.

During exogenous administration of androgens, endogenous testosterone release is inhibited through feedback inhibition of pituitary luteinizing hormone (LH). At large doses of exogenous androgens, spermatogenesis may also be suppressed through feedback inhibition of pituitary follicle stimulating hormone (FSH).

There is a lack of substantial evidence that androgens are effective in fractures, surgery, convalescence, and functional uterine bleeding.

Pharmacokinetics

Testosterone esters are less polar than free testosterone. Testosterone esters in oil injected intramuscularly are absorbed slowly from the lipid phase; thus, Testosterone Cypionate can be given at intervals of two to four weeks.

Testosterone in plasma is 98 percent bound to a specific testosterone-estradiol binding globulin, and about 2 percent is free. Generally, the amount of this sex-hormone binding globulin in the plasma will determine the distribution of testosterone between free and bound forms, and the free testosterone concentration will determine its half-life.

About 90 percent of a dose of testosterone injections is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites; about 6 percent of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver. Testosterone therapy is metabolized to various 17-keto steroids through two different pathways.

The half-life of Testosterone Cypionate, when injected intramuscularly, is approximately eight days.

In many tissues, the activity of testosterone therapy appears to depend on reduction to dihydrotestosterone, which binds to cytosol receptor proteins. The steroid-receptor complex is transported to the nucleus where it initiates transcription events and cellular changes related to androgen action.

Indications and Usage for Testosterone Cypionate description

Testosterone Cypionate description injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone.

  • Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy.
  • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation.

Safety and efficacy of Testosterone Cypionate description in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established.

Contraindications

  1. Known hypersensitivity to the drug
  2. Males with carcinoma of the breast
  3. Males with known or suspected carcinoma of the prostate gland
  4. Women who are or who may become pregnant
  5. Patients with serious cardiac, hepatic or renal disease

Warnings

Hypercalcemia may occur in immobilized patients. If this occurs, the drug should be discontinued.

Prolonged use of high doses of androgens (principally the 17-α alkyl-androgens) has been associated with the development of hepatic adenomas, hepatocellular carcinoma, and peliosis hepatis —all potentially life-threatening complications.

Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.

There have been postmarketing reports of venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients using testosterone products, such as Testosterone Cypionate description. Evaluate patients who report symptoms of pain, edema, warmth, and erythema in the lower extremity for DVT and those who present with acute shortness of breath for PE. If a venous thromboembolic event is suspected, discontinue treatment with Testosterone Cypionate description and initiate appropriate workup and management.

Long term clinical safety trials have not been conducted to assess the cardiovascular outcomes of testosterone replacement therapy in men. To date, epidemiologic studies and randomized controlled trials have been inconclusive for determining the risk of major adverse cardiovascular events (MACE), such as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death, with the use of testosterone compared to non-use. Some studies, but not all, have reported an increased risk of MACE in association with the use of testosterone replacement therapy in men. Patients should be informed of this possible risk when deciding whether to use or to continue to use Testosterone Cypionate description.

Edema, with or without congestive heart failure, may be a serious complication in patients with preexisting cardiac, renal or hepatic disease.

Gynecomastia may develop and occasionally persists in patients being treated for hypogonadism.

The preservative benzyl alcohol has been associated with serious adverse events, including the “gasping syndrome”, and death in pediatric patients. Although normal therapeutic doses of this product ordinarily deliver amounts of benzyl alcohol that are substantially lower than those reported in association with the “gasping syndrome”, the minimum amount of benzyl alcohol at which toxicity may occur is not known. The risk of benzyl alcohol toxicity depends on the quantity administered and the hepatic capacity to detoxify the chemical. Premature and low-birth weight infants may be more likely to develop toxicity.

Androgen therapy should be used cautiously in healthy males with delayed puberty. The effect on bone maturation should be monitored by assessing the bone age of the wrist and hand every 6 months. In children, androgen treatment may accelerate bone maturation without producing a compensatory gain in linear growth. This adverse effect may result in compromised adult stature. The younger the child the greater the risk of compromising final mature height.

This drug has not been shown to be safe and effective for the enhancement of athletic performance. Because of the potential risk of serious adverse health effects, this drug should not be used for such purpose.

Precautions

General

Patients with benign prostatic hypertrophy may develop acute urethral obstruction. Priapism or excessive sexual stimulation may develop. Oligospermia may occur after prolonged administration or excessive dosage. If any of these effects appear, the androgen should be stopped and if restarted, a lower dosage should be utilized.

Testosterone Cypionate description should not be used interchangeably with testosterone propionate description because of differences in duration of action.

Testosterone Cypionate description is not for intravenous use.

Information for Patients

Patients should be instructed to report any of the following: nausea, vomiting, changes in skin color, ankle swelling, too frequent or persistent erections of the penis.

Laboratory Tests

Hemoglobin and hematocrit levels (to detect polycythemia) should be checked periodically in patients receiving long-term androgen administration.

Serum cholesterol may increase during androgen therapy.

Drug Interactions

Androgens may increase sensitivity to oral anticoagulants. The dosage of the anticoagulant may require a reduction in order to maintain satisfactory therapeutic hypoprothrombinemia.

Concurrent administration of oxyphenbutazone and androgens may result in elevated serum levels of oxyphenbutazone.

In diabetic patients, the metabolic effects of androgens may decrease blood glucose and, therefore, insulin requirements.

Drug/Laboratory Test Interferences

Androgens may decrease levels of thyroxine-binding globulin, resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.

Carcinogenesis

Animal data

Testosterone has been tested by subcutaneous injection and implantation in mice and rats. The implant induced cervical-uterine tumors in mice, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats.

Human data

There are rare reports of hepatocellular carcinoma in patients receiving long-term therapy with androgens in high doses. Withdrawal of the drugs did not lead to regression of the tumors in all cases.

Geriatric patients treated with androgens may be at an increased risk of developing prostatic hypertrophy and prostatic carcinoma although conclusive evidence to support this concept is lacking.

Pregnancy

Teratogenic Effects

Pregnancy Category X. (See CONTRAINDICATIONS)

Benzyl alcohol can cross the placenta. See WARNINGS.

Nursing Mothers

Testosterone Cypionate description is not recommended for use in nursing mothers.

Pediatric Use

Safety and effectiveness in pediatric patients below the age of 12 years have not been established.

Adverse Reactions

The following adverse reactions in the male have occurred with some androgens:

Endocrine and urogenital: Gynecomastia and excessive frequency and duration of penile erections. Oligospermia may occur at high dosages.

Skin and Appendages: Hirsutism, male pattern of baldness, seborrhea, and acne.

Cardiovascular Disorders – myocardial infarction, stroke

Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.

Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (see WARNINGS).

Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.

Nervous system: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.

Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions.

Vascular Disorders: venous thromboembolism

Miscellaneous: Inflammation and pain at the site of intramuscular testosterone injection.

Testosterone Therapy Information